The immunogenicity of GSK’s recombinant hepatitis B vaccine in children: a systematic review of 30 years of experience

References

• World Health Organization. Hepatitis B vaccines: WHO position paper–recommendations. Vaccine. 2010;28:589–590.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health sector strategy on Viral hepatitis 2016–2021. Towards ending viral hepatitis. WHO/HIV/2016.06.
   Google Scholar
• Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20:992–1000.
   PubMed Web of Science ®Google Scholar
• Expanded programme on immunization. Global Advisory Group–part I. Wkly Epidemiol Rec. 1992;67:11–15. Epub 1992/01/17.
   PubMedGoogle Scholar
• World Health Organization. vaccine-preventable disease monitoring system, 2016 global summary.
   Google Scholar
• World Health Organization. Immunization coverage. Fact sheet Updated September 2016.
   Google Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266–6273.
   PubMed Web of Science ®Google Scholar
• Ng KP, Saw TL, Baki A, et al. Impact of the expanded program of immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol. 2005;194:163–168.
   PubMed Web of Science ®Google Scholar
• Chien YC, Jan CF, Kuo HS, et al. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28:126–135.
   PubMed Web of Science ®Google Scholar
• Safary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J Gastroenterol Hepatol. 2000;15:396–401.
   PubMed Web of Science ®Google Scholar
• Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612–2616.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA. 1989;261:3278–3281.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5:79–84.
   PubMedGoogle Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28:730–736.
   PubMed Web of Science ®Google Scholar
• Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000;355:561–565.
   PubMed Web of Science ®Google Scholar
• ECDC. European Centre for disease prevention and control [updated 2015 Mar 01]. Available from: http://www.ecdc.europa.eu/en/publications/surveillance_reports/Pages/index.aspx.
   Google Scholar
• World Health Organization. [cited 2016 Mar 21]. Available from: http://www.who.int/en/
   Google Scholar
• Centers for Disease Control and Prevention. [cited 2016Mar 21]. Available from: https://www.cdc.gov/
   Google Scholar
• Eurosurveillance 1996-2016. [cited 2016 Mar 21]. Available from: http://www.eurosurveillance.org/
   Google Scholar
• EUROHEP.NET. [cited 2016 Mar 21]. Available from: Hhttp://www.eurohep.net/
   Google Scholar
• Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179:489–492.
   PubMed Web of Science ®Google Scholar
• Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine. 1997;15:1624–1630.
   PubMed Web of Science ®Google Scholar
• Lee CY, Huang LM, Chang MH, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J. 1991;10:299–303. Epub 1991/04/01.
   PubMed Web of Science ®Google Scholar
• Lee PI, Lee CY, Huang LM, et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr. 1995;126:716–721. Epub 1995/05/01.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992;11:816–821.
   PubMed Web of Science ®Google Scholar
• Jaber L, Merlob P, Samra Z. Response to recombinant yeast‐derived hepatitis B vaccine in Arab infants. Int J Risk Saf Med. 1999;12:193–196.
   Google Scholar
• Cheang HK, Wong HT, Ho SC, et al. Immune response in infants after universal hepatitis B vaccination: a community-based study in Malaysia. Singapore Med J. 2013;54:224–226. Epub 2013/04/30.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28:3595–3601. Epub 2010/03/02.
   PubMed Web of Science ®Google Scholar
• Martins RM, Bensabath G, Arraes LC, et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz. 2004;99:865–871. Epub 2005/03/12.
   PubMed Web of Science ®Google Scholar
• Fagundes GD, Tabalipa Fde O, Silva J. Antibody levels in children after 10 years of vaccination against hepatitis B: a Brazilian community-based study. Rev Soc Bras Med Trop. 2012;45:260–262. Epub 2012/04/27.
   PubMed Web of Science ®Google Scholar
• Gilca V, De Serres G, Boulianne N, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine. 2013;31:448–451. Epub 2012/12/05.
   PubMed Web of Science ®Google Scholar
• Duval B, Gilca V, Boulianne N, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J. 2005;24:213–218. Epub 2005/03/08.
   PubMed Web of Science ®Google Scholar
• Goldfarb J, Baley J, Medendorp SV, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J. 1994;13:18–22. Epub 1994/01/01.
   PubMed Web of Science ®Google Scholar
• Heron L, Selnikova O, Moiseieva A, et al. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. Vaccine. 2007;25:2817–2822.
   PubMed Web of Science ®Google Scholar
• Halsey NA, Moulton LH, O’Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics. 1999;103:1243–1247. Epub 1999/06/03.
   PubMed Web of Science ®Google Scholar
• Schiff GM, Sherwood JR, Zeldis JB, et al. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health. 1995;16:12–17. Epub 1995/01/01.
   PubMed Web of Science ®Google Scholar
• Tsega E, Horton J, Nordenfelt E, et al. Antibody levels in Ethiopian children five years after vaccination with two different doses of hepatitis B vaccine: is there a need for booster vaccine? Can J Gastroenterol. 1998;12:57–60. Epub 1998/04/17.
   PubMed Web of Science ®Google Scholar
• Dumaidi K, Al-Jawabreh A. Persistence of anti-HBs Among Palestinian medical students after 18-22 years of vaccination: a cross-sectional study. Hepat Mon. 2015;15:e29325. Epub 2016/02/03.
   PubMed Web of Science ®Google Scholar
• Chiara F, Bartolucci GB, Cattai M, et al. Hepatitis B vaccination of adolescents: significance of non-protective antibodies. Vaccine. 2013;32:62–68. Epub 2013/11/06.
   PubMed Web of Science ®Google Scholar
• Behre U, Bleckmann G, Crasta PD, et al. Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother. 2012;8:813–818. Epub 2012/04/18.
   PubMed Web of Science ®Google Scholar
• Hartal M, Yavnai N, Galor I, et al. Seroprevalence of anti-HBs antibodies at young adulthood, before and after a booster vaccine dose, among medical personnel vaccinated in infancy. Vaccine. 2015;33:4878–4885. Epub 2015/08/02.
   PubMed Web of Science ®Google Scholar
• Ayerbe MC, Perez-Rivilla A. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol. 2001;17:150–156. Epub 2001/10/16.
   PubMed Web of Science ®Google Scholar
• Gabbuti A, Romano L, Blanc P, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007;25:3129–3132. Epub 2007/02/13.
   PubMed Web of Science ®Google Scholar
• Luna EJ, Moraes JC, Silveira L, et al. Efficacy and safety of the Brazilian vaccine against hepatitis B in newborns. Rev Saude Publica. 2009;43:1014–1020.
   PubMed Web of Science ®Google Scholar
• Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA. 1995;274:1209–1213. Epub 1995/10/18.
   PubMed Web of Science ®Google Scholar
• Ferreira CR, Yoshida CF, Mercadante LA, et al. Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 MCG). Rev Inst Med Trop Sao Paulo. 1993;35:89–92. Epub 1993/01/01.
   PubMedGoogle Scholar
• Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366:1379–1384. Epub 2005/10/18.
   PubMed Web of Science ®Google Scholar
• Avdicova M, Crasta PD, Hardt K, et al. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Vaccine. 2015;33:2727–2733. Epub 2014/06/26.
   PubMed Web of Science ®Google Scholar
• Leonardi S, Vitaliti G, Garozzo MT, et al. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Hum Vaccin Immunother. 2012;8:448–452. Epub 2012/03/01.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Martin JC, Liss CL, et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. Pediatr Infect Dis J. 2011;30:e109–113. Epub 2011/05/10.
   PubMed Web of Science ®Google Scholar
• Sapru A, Kulkarni PS, Bhave S, et al. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study. J Trop Pediatr. 2007;53:303–307. Epub 2007/05/05.
   PubMed Web of Science ®Google Scholar
• Aristegui J, Muniz J, Perez Legorburu A, et al. Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine. 1995;13:973–977. Epub 1995/08/01.
   PubMed Web of Science ®Google Scholar
• Al-Faleh FZ, Al-Jeffri M, Ramia S, et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect. 1999;38:167–170. Epub 1999/07/29.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Vadheim CM, Marcy SM, et al. Safety and immunogenicity of a recombinant hepatitis B vaccine administered to infants at 2, 4 and 6 months of age. The Kaiser-UCLA vaccine study group. Vaccine. 1996;14:811–816. Epub 1996/06/01.
   PubMed Web of Science ®Google Scholar
• Da Villa G, Romano L, Sepe A, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine. 2007;25:3133–3136. Epub 2007/02/07.
   PubMed Web of Science ®Google Scholar
• Milne A, Brawner TA, Dumbill PC, et al. Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J Med Virol. 1989;27:264–267. Epub 1989/03/01.
   PubMed Web of Science ®Google Scholar
• Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine. 2002;20:3472–3476. Epub 2002/09/26.
   PubMed Web of Science ®Google Scholar
• Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res. 2003;29:84–86. Epub 2003/05/21.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV vaccine’s protection and response to hepatitis B booster immunization in 5- to 7-year-old children in the Kohgiloyeh and Boyerahmad province, Iran. Hepat Mon. 2010;10:17–21. Epub 2010/01/01.
   PubMed Web of Science ®Google Scholar
• Avazova D, Kurbanov F, Tanaka Y, et al. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol. 2008;80:217–224. Epub 2007/12/22.
   PubMed Web of Science ®Google Scholar
• Blondheim O, Bader D, Abend M, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1998;79:F206–208. Epub 1999/04/09.
   PubMed Web of Science ®Google Scholar
• Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, et al. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine. 2002;20:1557–1562. Epub 2002/02/23.
   PubMed Web of Science ®Google Scholar
• Chirico G, Belloni C, Gasparoni A, et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics. 1993;92:717–719. Epub 1993/11/01.
   PubMed Web of Science ®Google Scholar
• Belloni C, Pistorio A, Tinelli C, et al. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine. 2000;18:1307–1311. Epub 2000/01/05.
   PubMed Web of Science ®Google Scholar
• Golebiowska M, Kardas-Sobantka D, Chlebna-Sokol D, et al. Hepatitis B vaccination in preterm infants. Eur J Pediatr. 1999;158:293–297. Epub 1999/04/17.
   PubMed Web of Science ®Google Scholar
• Lau YL, Tam AY, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr. 1992;121:962–965. Epub 1992/12/01.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, et al. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed. 1997;77:F47–51. Epub 1997/07/01.
   PubMed Web of Science ®Google Scholar
• Fang JW, Lai CL, Chung HT, et al. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr. 1994;40:104–107. Epub 1994/04/01.
   PubMed Web of Science ®Google Scholar
• Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol. 1994;10:541–547. Epub 1994/10/01.
   PubMed Web of Science ®Google Scholar
• Vranckx R, Alisjahbana A, Ngantung W, et al. Anti-HBs kinetics after HBV vaccination in neonates. Clin Diagn Virol. 1994;2:343–348. Epub 1994/10/01.
   PubMedGoogle Scholar
• Mutwa PR, Boer KR, Rusine JB, et al. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda. Pediatr Infect Dis J. 2013;32:246–251. Epub 2012/09/15.
   PubMed Web of Science ®Google Scholar
• Arrazola MP, De Juanes JR, Ramos JT, et al. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol. 1995;45:339–341. Epub 1995/03/01.
   PubMed Web of Science ®Google Scholar
• Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr. 2011;56:325–332.
   PubMed Web of Science ®Google Scholar
• Pollack TM, Trang Le TT, Ngo L, et al. Response to hepatitis B vaccination among HIV-infected adults in Vietnam. J Virus Erad. 2016;2:102–106.
   PubMed Web of Science ®Google Scholar
• Sodhi JS, Raja W, Zargar SA, et al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy. Indian J Gastroenterol. 2015;34:372–379. Epub 2015/11/05.
   PubMed Web of Science ®Google Scholar
• Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol. 1996;13:425–431. Epub 1996/09/01.
   PubMed Web of Science ®Google Scholar
• Yetgin S, Tunc B, Koc A, et al. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res. 2001;25:647–649. Epub 2001/06/09.
   PubMed Web of Science ®Google Scholar
• Goyal S, Pai SK, Kelkar R, et al. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res. 1998;22:193–195. Epub 1998/05/21.
   PubMed Web of Science ®Google Scholar
• Somjee S, Pai S, Kelkar R, et al. Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Leuk Res. 1999;23:365–367. Epub 1999/05/06.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down’s syndrome. Vaccine. 1990;8(Suppl):S53–55. discussion S60-52. Epub 1990/03/01.
   PubMedGoogle Scholar
• Van Damme P, Vranckx R, Safary A, et al. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med. 1989;87:26s–29s. Epub 1989/09/04.
   PubMed Web of Science ®Google Scholar
• Vellinga A, Van Damme P, Weyler JJ, et al. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 1999;17:602–606. Epub 1999/03/13.
   PubMed Web of Science ®Google Scholar
• Ertekin V, Tosun MS, Selimoglu MA. Is there need for a new hepatitis B vaccine schedule for children with celiac disease? Hepat Mon. 2011;11:634–637. Epub 2011/12/06.
   PubMed Web of Science ®Google Scholar
• Chinchai T, Chirathaworn C, Praianantathavorn K, et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol. 2009;22:125–130. Epub 2009/03/31.
   PubMed Web of Science ®Google Scholar
• De Serres G, Duval B, Boulianne N, et al. Importance of attributable risk in monitoring adverse events after immunization: hepatitis B vaccination in children. Am J Public Health. 2001;91:313–315. Epub 2001/02/24.
   PubMed Web of Science ®Google Scholar
• Optimizing the Hepatitis B vaccination schedules. Cochrane targeted update. 2016.
   Google Scholar
• Engerix B. Summary of product charactertistics. [cited 2017 Feb 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Engerix_B_30/WC500011088.pdf
   Google Scholar
• Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999;103:E14.
   PubMed Web of Science ®Google Scholar
• Czajka H, Lauterbach R, Pawlik D. Vaccination of preterm infants by polyvalent vaccines: immunogenicity and safety- review of literature. Dev Period Med. 2014;18:360–366.
   PubMedGoogle Scholar
• Omenaca F, Garcia-Sicilia J, Boceta R, et al. Hepatitis B response of premature infants after primary and booster immunisation with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus/haemophilus influenzae type B vaccine. Infect Dis Obstet Gynecol. 2010;2010:802503.
   PubMedGoogle Scholar
• Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.
   PubMed Web of Science ®Google Scholar
• Tosti ME, Alfonsi V, Lacorte E, et al. Acute hepatitis B after the implementation of universal vaccination in Italy: results from 22 years of surveillance (1993-2014). Clin Infect Dis. 2016;62:1412–1418.
   PubMed Web of Science ®Google Scholar
• Su WJ, Liu CC, Liu DP, et al. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis. 2012;205:757–762.
   PubMed Web of Science ®Google Scholar
• Hsu HY, Chang MH, Ni YH, et al. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology. 2015;61:1183–1191.
   PubMed Web of Science ®Google Scholar
• Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. New Eng J Med. 2011;364:236–247.
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat. 2011;18:369–375.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. The New Eng J Med. 2001;344:327–332.
   PubMed Web of Science ®Google Scholar
• DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504–509.
   PubMedGoogle Scholar
• Ramagopalan SV, Valdar W, Dyment DA, et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiol. 2009;32:257–262.
   PubMed Web of Science ®Google Scholar
• Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–976.
   PubMed Web of Science ®Google Scholar